Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CHRNA1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
2 CHRNA1 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
3 CHRNA1 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
4 CHRNA2 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
5 CHRNA2 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
6 CHRNA2 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
7 CHRNA3 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
8 CHRNA3 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
9 CHRNA3 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
10 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
11 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
12 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
13 CHRNA5 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
14 CHRNA5 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
15 CHRNA5 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
16 CHRNA7 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
17 CHRNA7 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
18 CHRNA7 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
19 CHRNB1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
20 CHRNB1 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
21 CHRNB1 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
22 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
23 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
24 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
25 CHRNB3 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
26 CHRNB3 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
27 CHRNB3 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
28 CHRNB4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
29 CHRNB4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
30 CHRNB4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
31 CHRND [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
32 CHRND [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
33 CHRND [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
34 CHRNE [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
35 CHRNE [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
36 CHRNE [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
37 CHRNG [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
38 CHRNG [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
39 CHRNG [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
40 CCR5 [9] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis D06670 Maraviroc [2] 46, 84
41 DHFR [5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate [38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
42 DHFR [5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate [38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
43 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
44 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07077 Ambrisentan [7] 51, 84, 85, 86, 88, 210, 211
45 EDNRA [7] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
46 EDNRB [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
47 EDNRB [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
48 DHFR2 [5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate [38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
49 DHFR2 [5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate [38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
50 MTOR [51] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus [41] 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
51 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
52 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
53 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
54 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
55 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
56 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
57 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
58 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
59 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
60 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
61 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
62 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
63 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
64 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
65 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
66 NR3C1 [1] Neuroactive ligand-receptor interaction D00292 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
67 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [20] 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
68 NR3C1 [1] Neuroactive ligand-receptor interaction D00472 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
69 NR3C1 [1] Neuroactive ligand-receptor interaction D00473 Prednisone [22] 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
70 NR3C1 [1] Neuroactive ligand-receptor interaction D00751 Methylprednisolone [20] 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
71 NR3C1 [1] Neuroactive ligand-receptor interaction D00975 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
72 NR3C1 [1] Neuroactive ligand-receptor interaction D00979 Methylprednisolone [20] 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
73 NR3C1 [1] Neuroactive ligand-receptor interaction D00980 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
74 NR3C1 [1] Neuroactive ligand-receptor interaction D00981 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
75 NR3C1 [1] Neuroactive ligand-receptor interaction D00982 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
76 NR3C1 [1] Neuroactive ligand-receptor interaction D01239 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
77 NR3C1 [1] Neuroactive ligand-receptor interaction D01510 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
78 NR3C1 [1] Neuroactive ligand-receptor interaction D01615 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
79 NR3C1 [1] Neuroactive ligand-receptor interaction D01632 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
80 NR3C1 [1] Neuroactive ligand-receptor interaction D01703 Ciclesonide [1] 84
81 NR3C1 [1] Neuroactive ligand-receptor interaction D01948 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
82 NR3C1 [1] Neuroactive ligand-receptor interaction D01998 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
83 NR3C1 [1] Neuroactive ligand-receptor interaction D02156 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
84 NR3C1 [1] Neuroactive ligand-receptor interaction D02174 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
85 NR3C1 [1] Neuroactive ligand-receptor interaction D02591 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
86 NR3C1 [1] Neuroactive ligand-receptor interaction D02592 Dexamethasone [11] 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
87 NR3C1 [1] Neuroactive ligand-receptor interaction D03301 Prednisolone [16] 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
88 NR3C1 [1] Neuroactive ligand-receptor interaction D05000 Methylprednisolone [20] 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
89 NR3C1 [1] Neuroactive ligand-receptor interaction D05001 Methylprednisolone [20] 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
90 NR3C1 [1] Neuroactive ligand-receptor interaction D05002 Methylprednisolone [20] 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
91 GUCY1A2 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat [6] 51, 84, 86, 88, 225, 299
92 GUCY1A1 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat [6] 51, 84, 86, 88, 225, 299
93 GUCY1B1 [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat [6] 51, 84, 86, 88, 225, 299
94 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00887 Atorvastatin [18] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
95 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D07474 Atorvastatin [18] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
96 IL1A [21] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
97 IL1B [44] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
98 IL1B [44] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09315 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
99 IL1R1 [13] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra [19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
100 IL6 [51] EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
101 IL6R [12] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D10161 Sarilumab [5] 41, 46, 84, 107, 271
102 IL10 [22] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
103 IL12A [25] Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
104 IL12B [25] Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
105 IMPDH1 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid [36] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
106 IMPDH2 [3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid [36] 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
107 JAK1 [27] EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
108 JAK2 [24] EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
109 JAK3 [15] Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
110 MC2R [5] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome D00146 Corticotropin [15] 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
111 SERPINC1 [1] Complement and coagulation cascades D07510 Heparin [8] 84, 107, 224, 226, 280, 299, 316, 317
112 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast [2] 84, 299
113 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast [2] 84, 299
114 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast [2] 84, 299
115 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast [2] 84, 299
116 IL23A [9] Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
117 CHRNA9 [2] Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
118 CHRNA9 [2] Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
119 CHRNA9 [2] Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
120 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
121 CHRNA10 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [1] 84
122 CHRNA10 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [1] 84
123 CHRNA10 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [1] 84
124 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D02721 Iloprost [4] 51, 84, 85, 86
125 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D06213 Treprostinil [6] 51, 84, 85, 86, 88, 210
126 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D09994 Selexipag [6] 47, 51, 70, 84, 86, 88
127 SCN1A [1] Dopaminergic synapse D00358 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
128 SCN1A [1] Dopaminergic synapse D02086 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
129 SCN1A [1] Dopaminergic synapse D08127 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
130 SCN2A [1] Taste transduction D00358 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
131 SCN2A [1] Taste transduction D02086 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
132 SCN2A [1] Taste transduction D08127 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
133 SCN3A [1] Taste transduction D00358 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
134 SCN3A [1] Taste transduction D02086 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
135 SCN3A [1] Taste transduction D08127 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
136 SCN5A [1] Adrenergic signaling in cardiomyocytes D00358 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
137 SCN5A [1] Adrenergic signaling in cardiomyocytes D02086 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
138 SCN5A [1] Adrenergic signaling in cardiomyocytes D08127 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
139 SCN9A [1] Taste transduction D00358 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
140 SCN9A [1] Taste transduction D02086 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
141 SCN9A [1] Taste transduction D08127 Lidocaine [7] 84, 86, 107, 168, 226, 231, 256
142 CCL2 [17] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
143 SLC6A2 [1] Synaptic vesicle cycle D01296 Methylphenidate [4] 84, 113, 179, 206
144 SLC6A2 [1] Synaptic vesicle cycle D04999 Methylphenidate [4] 84, 113, 179, 206
145 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D01296 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
146 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D03215 Armodafinil [3] 6, 13, 84
147 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
148 SSTR2 [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion D00442 Octreotide [7] 67, 75, 84, 85, 89, 193, 227
149 SSTR2 [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion D06495 Octreotide [7] 67, 75, 84, 85, 89, 193, 227
150 TNF [67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
151 TNF [67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
152 TNF [67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02597 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
153 TNF [67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02598 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
154 TNF [67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D04358 Golimumab [8] 46, 56, 84, 96, 97, 107, 270, 271
155 TYK2 [16] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
156 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00187 Ergocalciferol [6] 46, 49, 84, 96, 97, 299
157 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol [25] 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
158 IL1R2 [7] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra [19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
159 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02008 Tadalafil [7] 6, 51, 75, 84, 86, 113, 210
160 CHRNA6 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
161 CHRNA6 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05156 Nicotine [3] 6, 13, 84
162 CHRNA6 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05157 Nicotine [3] 6, 13, 84
163 MS4A1 [1] Hematopoietic cell lineage D02994 Rituximab [21] 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
164 CD80 [10] Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
165 CD86 [12] Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
166 NR1H4 [1] Bile secretion D00734 Ursodeoxycholic acid [9] 84, 93, 94, 95, 96, 97, 234, 296, 299